Cover Image
市場調查報告書

處方藥改列成藥醫藥品:成功策略 & 機會

Rx-to-OTC Switch - Success Strategies & Opportunities

出版商 Nicholas Hall & Company 商品編碼 553345
出版日期 內容資訊 英文 252 Pages
訂單完成後即時交付
價格
Back to Top
處方藥改列成藥醫藥品:成功策略 & 機會 Rx-to-OTC Switch - Success Strategies & Opportunities
出版日期: 2017年12月21日 內容資訊: 英文 252 Pages
簡介

本報告提供全球改列(從處方藥 (Rx)轉換到成藥 (OTC) ) 環境的相關調查,成功的機會及障礙評估,改列成功背後的不可缺少的要素的調查,及主要OTC市場的各國分析等。

序文

簡介

改列(從處方藥 (Rx)轉換到成藥 (OTC) )

改列策略

各地區的分析

改列品牌的案例研究

  • Abreva (GSK)
  • Advil (Pfizer)
  • Alesion (SSP / Sanofi)
  • Aleve (Bayer)
  • Allegra (Sanofi)
  • Alli (GSK)
  • Clamelle (Allergan)
  • Claritin (Bayer)
  • Dexak (Berlin Chemie / Menarini)
  • Differin (Galderma / Nestle)
  • Dovonex (Leo Laboratories)
  • ellaOne (HRA Pharma)
  • Flonase (GSK)
  • Formigran (GSK)
  • Hascovir Control (Hasco-Lek)
  • Lamisil (GSK)
  • Loxonin S (Daiichi Sankyo)
  • Maloff Protect (Glenmark)
  • MaxOn Active (Adamed)
  • Meloxicam Adamed (Adamed), Mel (Hasco-Lek)
  • MiraLAX (Bayer)
  • Mucinex (RB)
  • Nasacort (Sanofi)
  • Nexium 24HR (Pfizer)
  • Nicorette (J&J, GSK)
  • Pepcid AC (J&J)
  • Plan B (Foundation Consumer Healthcare)
  • Prevacid 24HR (GSK)
  • Prilosec OTC (P&G)
  • Rhinocort (J&J)
  • RiUP (Taisho)
  • Silvasta (Douglas Pharmaceuticals)
  • Viagra Connect (Pfizer)
  • Volini (Ranbaxy / Sun Pharma)
  • Voltaren (GSK)
  • Xenical (Roche)
  • Xyzal (Sanofi, UCB)
  • Zyrtec (J&J, UCB)

預測

結論

目錄

This updated edition of the best-selling 2014 report again features the knowledge and insight of Switch expert Joseph McGovern along with Nicholas Hall's industry expertise and sales data. The collaborative report takes an in-depth look at the global switch environment, assessing the opportunities and the barriers to success. It investigates the essential factors behind successful switches. Furthermore, the report offers country breakdowns of the key OTC markets - providing insight into the local switch environment, the latest switches and regulatory changes - to give you the knowledge needed no matter where you are looking to make a switch.

Table of Contents

  • Definitions & methodology

Foreword by Joseph McGovern (2 pages)

Introduction (3 pages)

Switch Learnings (19 pages)

  • Reasons to Switch (5pp)
  • Switch is critical for growth of consumer health
  • 9 of the world's Top 20 are switched products
  • Global Top 20 OTC brands 2016
  • Switch increases access to treatment
  • Potential stages in an Rx-to-OTC switch
  • Switch increases healthy outcomes
  • Healthy outcomes for NRT's self-care availability
  • Switch is a vital part of healthcare
  • Switch drivers (4pp)
  • Rising cost of healthcare
  • Pharmacy Point of care
  • Collaborative care
  • The rise of technology
  • Better educated consumers
  • Barriers to successful switch (4pp)
  • A challenging time for switch
  • Navigating the stages of access
  • The pros & cons of BTC status
  • Potential stages in a switch
  • Dual status
  • Lessons from difficult switches (5pp)
  • Zocor Heart-Pro
  • Flomax Relief
  • Oxytrol for Women
  • Zegerid OTC
  • Lipitor (did not switch OTC in US after failure of Actual Use Study)
  • Key lessons from difficult switches

Switch Strategies (28 pages)

  • The key to switch (1pp)
  • Switch checklist
  • Types of switch (2pp)
  • Different forms of switch
  • Complete switch: all indications and doses move from Rx to OTC
  • Dual status (a medicine is both Rx and OTC)
  • Collaborative care
  • The potential of pharmacies (2pp)
  • Community pharmacies may hold key to next generation of switches outside of the US
  • Geographical disparity in switch (1pp)
  • The big geographical divide
  • The issue of responsibility
  • Choosing the right brand to switch (4pp)
  • What to switch?
  • Researching the potential consumer
  • Evaluating the brand's OTC attractiveness
  • Consider the regulatory perspective
  • Commercial potential
  • Competitive landscape presently
  • Category growth potential
  • Ease of in-licensing
  • Competitive landscape in future
  • OTCs form a vital part of the healthcare system (1pp)
  • Building the case for switch - key points
  • Key strategies for successful switch (6pp)
  • Environmental management
  • Gain advocates / stakeholders
  • Case study: Alli Advisory Committee meeting (a regulatory success)
  • Make the public health case
  • Reach out to private healthcare providers
  • US Managed Care is a critical partner for switch
  • Consumer support programmes
  • Alli (GSK) Nicorette (GSK)
  • Ten recommendations for switch (2pp)
  • Ten recommendations for switch (according to the EU)
  • Building a switch team (2pp)
  • Team setup
  • Core team
  • Regulatory & medical team
  • Marketing team
  • Supply team
  • Professional marketing team
  • Go-to-market team
  • The importance of marketing in switch (5pp)
  • Creating & building brands
  • Focus on claims or status?
  • Pepcid Tagamet
  • Targeting the retailer
  • Launch and beyond (1pp)
  • Key steps before and after launch

Region by Region Analysis (76 pages)

  • Regional differences (2pp)
  • USA Europe, Japan, Canada, Australia
  • Rest of world
  • Understanding your country system
  • North America - Canada (3pp)
  • Canada
  • Canada OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Switch process & developments
  • Recent switches in Canada
  • North America - USA (5pp)
  • USA
  • USA OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Switch process & developments
  • Recent switches in USA
  • FDA's PARADIGM SHIFT TO EXPAND NON-PRESCRIPTION ACCESS?
  • USA Top 10 Rx-to-OTC switches since 2000 by sales mid-2017
  • Fundamentals of switching in the US (10pp) A switch programme in the US must prove the consumer can...
  • Early communication is vital
  • Label development
  • Agreeing messages and how to communicate
  • Consumer studies
  • Label comprehension study
  • Self-selection study
  • Actual use study
  • Issues and challenges of actual use studies
  • Key principles of actual use studies
  • Europe (2pp)
  • EU's Centralised Procedure for switch
  • Key centralised switches in the EU
  • Western Europe - France (3pp)
  • France
  • France OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in France
  • Switch process & developments
  • Western Europe - Germany (3pp)
  • Germany
  • Germany OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in Germany
  • Switch process & developments
  • Western Europe - Italy (3pp)
  • Italy
  • Italy OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in Italy
  • Switch process & developments
  • Western Europe - Spain (3pp)
  • Spain
  • Spain OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in Spain
  • Switch process & developments
  • Western Europe - UK (4pp)
  • UK
  • UK OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in UK
  • Switch process & developments
  • Patient Group Direction service allows pharmacist dispensing of certain Rx medicines
  • Western Europe (1pp)
  • Other regional developments
  • C&E Europe - Poland (4pp)
  • Poland
  • Poland OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches (selected) in Poland
  • Switch process & developments
  • Analgesics
  • CCA
  • GIs
  • Derma Lifestyle OTCs
  • C&E Europe - Russia (3pp)
  • Russia
  • Russia OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in Russia
  • Switch process & developments
  • Asia-Pacific - Australia (4pp)
  • Australia
  • Australia OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in Australia
  • Switch process & developments
  • Asia-Pacific - China (3pp)
  • China
  • China OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in China
  • Switch process & developments
  • Asia-Pacific - India (3pp)
  • India
  • India OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in India
  • Switch process & developments
  • Asia-Pacific - Japan (5pp)
  • Japan
  • Japan OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Recent switches (selected) in Japan
  • Distribution
  • Switch process & developments
  • Asia-Pacific - New Zealand (4pp)
  • New Zealand
  • New Zealand OTC sales 2012-16
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in New Zealand
  • Switch process & developments
  • Focus on Pharmacy Point of Care in New Zealand
  • Asia-Pacific - South Korea (3pp)
  • South Korea
  • South Korea OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in South Korea
  • Switch process & developments
  • Latin America - Brazil (5pp)
  • Brazil
  • Brazil OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in Brazil
  • Switch process & developments
  • Ingredients proposed for switch to OTC status in Brazil 2017
  • Latin America - Mexico (3pp)
  • Mexico
  • Mexico OTC sales mid-2016 & mid-2017
  • Overview
  • OTC classification
  • Distribution
  • Recent switches in Mexico
  • Switch process & developments

Case studies of switched brands (86pp)

Abreva (GSK) (2pp)

  • Abreva OTC sales 2012-16
  • Abreva OTC sales by market 2016
  • Key switch elements

Advil (Pfizer) (2pp)

  • Advil OTC sales 2012-16
  • Advil OTC sales by market 2016
  • Key switch elements

Alesion (SSP / Sanofi) (2pp)

  • Alesion OTC sales 2012-16
  • Key switch elements

Aleve (Bayer) (3pp)

  • Aleve OTC sales 2012-16
  • Aleve OTC sales by market 2016
  • Key switch elements

Allegra (Sanofi) (3pp)

  • Allegra OTC sales 2012-16
  • Allegra OTC sales by market 2016
  • Key switch elements

Alli (GSK) (3pp)

  • Alli OTC sales 2012-16
  • Alli OTC sales by market 2016
  • Key switch elements

Clamelle (Allergan) (2pp)

  • Key switch elements

Claritin (Bayer) (3pp)

  • Claritin OTC sales 2012-16
  • Claritin OTC sales by market 2016
  • Key switch elements

Dexak (Berlin Chemie / Menarini) (1pp)

  • Dexak OTC sales 2012-16
  • Key switch elements

Differin (Galderma / Nestlé) (2pp)

  • Key switch elements

Dovonex (Leo Laboratories) (1pp)

  • Key switch elements

ellaOne (HRA Pharma) (2pp)

  • ellaOne OTC sales 2012-16
  • ellaOne OTC sales by market 2016
  • Key switch elements

Flonase (GSK) (5pp)

  • Flonase OTC sales 2012-16
  • Flonase OTC sales by market 2016
  • The mechanics of Flonase's US Rx-to-OTC switch
  • Key switch elements

Formigran (GSK) (2pp)

  • Formigran OTC sales 2012-16
  • Key switch elements

Hascovir Control (Hasco-Lek) (1pp)

  • Key switch elements

Lamisil (GSK) (2pp)

  • Lamisil OTC sales 2012-16
  • Lamisil OTC sales by market 2016
  • Key switch elements

Loxonin S (Daiichi Sankyo) (2pp)

  • Loxonin S OTC sales 2012-16
  • Key switch elements

Maloff Protect (Glenmark) (2pp)

  • Key switch elements

MaxOn Active (Adamed) (1pp)

  • MaxOn Active OTC sales 2012-16
  • Key switch elements

Meloxicam Adamed (Adamed), Mel (Hasco-Lek) (1pp)

  • Key switch elements

MiraLAX (Bayer) (2pp)

  • MiraLAX OTC sales 2012-16
  • MiraLAX OTC sales by market 2016
  • Key switch elements

Mucinex (RB) (3pp)

  • Mucinex OTC sales 2012-16
  • Key switch elements

Nasacort (Sanofi) (3pp)

  • Nasacort OTC sales 2012-16
  • Nasacort OTC sales by market 2016
  • Key switch elements

Nexium 24HR (Pfizer) (4pp)

  • Nexium 24HR OTC sales 2012-16
  • Nexium 24HR OTC sales by market 2016
  • Key switch elements

Nicorette (J&J, GSK) (2pp)

  • Nicorette OTC sales 2012-16
  • Nicorette OTC sales by market 2016
  • Key switch elements

Pepcid AC (J&J) (2pp)

  • Pepcid AC OTC sales 2012-16
  • Pepcid AC OTC sales by market 2016
  • Key switch elements

Plan B (Foundation Consumer Healthcare) (2pp)

  • Plan B OTC sales 2012-16
  • Plan B OTC sales by market 2016
  • Key switch elements

Prevacid 24HR (GSK) (2pp)

  • Prevacid 24HR OTC sales 2012-16
  • Key switch elements

Prilosec OTC (P&G) (2pp)

  • Prilosec OTC OTC sales 2012-16
  • Key switch elements

Rhinocort (J&J) (2pp)

  • Rhinocort OTC sales 2012-16
  • Rhinocort OTC sales by market 2016
  • Key switch elements

RiUP (Taisho) (2pp)

  • RiUP OTC sales 2012-16
  • Key switch elements

Silvasta (Douglas Pharmaceuticals) (2pp)

  • Silvasta OTC sales 2012-16
  • Key switch elements

Viagra Connect (Pfizer) (3pp)

  • Key switch elements

Volini (Ranbaxy / Sun Pharma) (2pp)

  • Volini OTC sales 2012-16
  • Key switch elements

Voltaren (GSK) (3pp)

  • Voltaren OTC sales 2012-16
  • Voltaren OTC sales by market 2016
  • Key switch elements

Xenical (Roche) (2pp)

  • Xenical OTC sales 2012-16
  • Key switch elements

Xyzal (Sanofi, UCB) (3pp)

  • Xyzal OTC sales 2012-16
  • Xyzal OTC sales by market 2016
  • Key switch elements

Zyrtec (J&J, UCB) (2pp)

  • Zyrtec OTC sales 2012-16
  • Zyrtec OTC sales by market 2016
  • Key switch elements

Looking Forward (26 pages)

  • Introduction (1pp)
  • Potential switch areas - Analgesics (4pp)
  • Migraine
  • Osteoarthritis / rheumatism
  • Others
  • Potential switch areas - Cough, cold & allergy (4pp)
  • Allergy
  • Cold & flu
  • Topical decongestants
  • Potential switch areas - Gastrointestinals (2pp)
  • Antacids
  • IBS treatments
  • Potential switch areas - Derma (2pp)
  • Antifungals
  • Eczema & psoriasis
  • Cold sore treatments
  • Potential switch areas - Lifestyle OTCs (12pp)
  • Daily oral contraceptives
  • Emergency hormonal contraception
  • Erectile dysfunction
  • Topical treatment of erectile dysfunction
  • Cholesterol reduction
  • Overactive bladder
  • Opioid overdose
  • Urinary tract infections
  • Insomnia

Conclusion (5pp)

  • Key switch learnings
  • 10 key switch lessons
Back to Top